Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

H. Lundbeck A Director's Dealing 2026

Feb 4, 2026

3367_rns_2026-02-04_fb7c5008-233c-42c4-9f5b-663f2f5ac1a1.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

{0}------------------------------------------------

CORPORATE RELEASE

Valby, Denmark, February 4, 2026

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Charl van Zyl
2. Reason for the notification
a) Position/status President & CEO
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 conducted Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
a) Description of the financial
instrument, type of instrument
Shares
Identification code B-shares: DK0061804770
b) Nature of the transaction Other transaction (vesting of Restricted Shares)
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 40.46 90,726
d) Aggregated information
- Aggregated volume
- Price
3,670,773.96 DKK
e) Date of the transaction 2026-02-04
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name
Barendina (Dianne) Hol
2. Reason for the notification
a) Position/status
Executive Vice President, People & Culture

H. Lundbeck A/S Ottiliavej 9 2500 Valby, DK

CVR number: 56759913 LEI code: 5493006R4KC2OI5D3470 E-mail [email protected] www.lundbeck.com

{1}------------------------------------------------

b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the financial
instrument, type of instrument
Shares
Identification code B-shares: DK0061804770
b) Nature of the transaction Other transaction (vesting of Restricted Shares)
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 40.46 125,934
d) Aggregated information
- Aggregated volume
- Price
5,095,289.64 DKK
e) Date of the transaction 2026-02-04
f) Place of the transaction NASDAQ Copenhagen XCSE
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Joerg Hornstein
2. Reason for the notification
a) Position/status Executive Vice President & CFO
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the financial
instrument, type of instrument
Shares
Identification code B-shares: DK0061804770
b) Nature of the transaction Other transaction (vesting of Restricted Shares)
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 40.46 79,591
d) Aggregated information
- Aggregated volume
- Price
3,220,251.86 DKK

{2}------------------------------------------------

f) Place of the transaction NASDAQ Copenhagen XCSE
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Johan Luthman
2. Reason for the notification
a) Position/status Executive Vice President, Research & Development
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 conducted Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
a) Description of the financial
instrument, type of instrument
Shares
Identification code B-shares: DK0061804770
b) Nature of the transaction Other transaction (vesting of Restricted Shares)
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 40.46 83,051
Aggregated information
d) - Aggregated volume
- Price
3,360,243.46 DKK
e) Date of the transaction 2026-02-04
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Lars Bang
2. Reason for the notification
a) Position/status Executive Vice President, Product Development & Supply
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the financial
instrument, type of instrument
Shares
Identification code B-shares: DK0061804770

{3}------------------------------------------------

b) Nature of the transaction Other transaction (vesting of Restricted Shares)
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 40.46 74,339
d) Aggregated information
- Aggregated volume
- Price
3,007,755.94 DKK
e) Date of the transaction 2026-02-04
f) Place of the transaction NASDAQ Copenhagen XCSE
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Michala Fischer-Hansen
2. Reason for the notification
a) Position/status Operations Executive Vice President, Head of Europe & International
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4
a)
conducted
Description of the financial
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
Shares
b) instrument, type of instrument
Identification code
Nature of the transaction
B-shares: DK0061804770
Other transaction (vesting of Restricted Shares)
c) Price(s) and volume(s) Price(s) Volume(s)
DKK 40.46 22,930
d) Aggregated information
- Aggregated volume
- Price
927,747.8 DKK
e) Date of the transaction 2026-02-04
f) Place of the transaction NASDAQ Copenhagen XCSE

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities mean inter alia:

  • spouse or cohabitant
  • dependent children
  • legal entities in which the executive has a controlling influence.

{4}------------------------------------------------

Contacts

Jens Høyer Anders Crillesen JSH[email protected] [email protected] +45 30 83 45 01 +45 29 79 12 86

Vice President, Head of Investor Relations Head of Media Relations, Corp. Communication

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long-term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.